AtlantiCare Pioneers Robotic Nipple-Sparing Mastectomy in the Tri-State Area

AtlantiCare Pioneers Robotic Nipple-Sparing Mastectomy

Recently, AtlantiCare made a groundbreaking announcement, becoming the first healthcare system in the tri-state area to offer robotic nipple-sparing mastectomy (RNSM) utilizing the da Vinci Single Port surgical system. This remarkable advancement in breast cancer surgery aims to provide patients with more minimally invasive treatment options. The procedure will be performed by Dr. Kay Yoon-Flannery, a prominent figure in the field and Chief of Women's Oncology at AtlantiCare Cancer Care Institute, at the AtlantiCare Regional Medical Center located in Atlantic City.

Dr. Yoon-Flannery emphasizes the emotional and personal nature of the decision to undergo a mastectomy, highlighting that the introduction of robotic nipple-sparing mastectomy is a significant leap towards helping women not only survive cancer but also preserve their self-identity and improve their quality of life.

Having trained in South Korea through an international robotic breast surgery observership, Dr. Yoon-Flannery is echoing her commitment to enhancing patient care through innovative techniques. The recent approval of the da Vinci SP system by the FDA marks a notable milestone in breast cancer treatment. The system offers numerous benefits including a single, smaller incision, reduced risk of complications related to blood flow to the skin and nipple, and the potential to maintain nipple sensation.

Moreover, the potential for a more natural look after reconstruction is an attractive option for many patients, underscoring the importance of this development. As the sole healthcare provider in the tri-state area to offer this procedure for both cancer treatment and risk-reduction in high-risk individuals, AtlantiCare positions itself at the forefront of modern breast cancer care.

Dr. Yoon-Flannery stresses the necessity of innovation in oncology for improving patient experiences. By introducing this advanced procedure, AtlantiCare aims to address the holistic needs of patients, fostering healing while supporting their confidence and dignity. This initiative also underscores AtlantiCare's dedication to providing top-tier, compassionate care utilizing cutting-edge technology.

The addition of robotic nipple-sparing mastectomy complements AtlantiCare's already comprehensive cancer program, which integrates a multidisciplinary team approach. The Women's Oncology team harmonizes breast, gynecologic, and genetic cancer services, thereby creating a coordinated continuum of care that encompasses prevention, detection, treatment, survivorship, and support.

Thanks to AtlantiCare's collaboration with the Cleveland Clinic Cancer Institute, patients have access to globally recognized cancer expertise and advanced research opportunities, including clinical trials. This partnership provides patients with the advantage of tumor review boards, second opinions, and innovative treatment solutions from world-renowned cancer specialists, thereby enhancing the quality of care provided.

In summary, AtlantiCare is pioneering significant advancements in breast cancer treatment through technology and patient-centered care, aiming to improve the lives of individuals facing breast cancer. As part of an award-winning integrated healthcare system in Egg Harbor Township, New Jersey, AtlantiCare serves a vast community across several counties with a commitment to health innovation and building healthier communities, one person at a time. For additional information, prospective patients and loved ones are encouraged to visit atlanticare.org or call 1-888-569-1000 for assistance.